BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schwartz GG, Ballantyne CM. Existing and emerging strategies to lower Lipoprotein(a). Atherosclerosis 2022;349:110-22. [DOI: 10.1016/j.atherosclerosis.2022.04.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Choi R, Lee SG, Lee EH. Lipoprotein(a) in the Korean Pediatric Population Visiting Local Clinics and Hospitals. Nutrients 2022;14:2820. [PMID: 35889777 DOI: 10.3390/nu14142820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kronenberg F. Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill? Atherosclerosis 2022;349:123-35. [PMID: 35606072 DOI: 10.1016/j.atherosclerosis.2022.04.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
3 Arsenault BJ, Kamstrup PR. Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective. Atherosclerosis 2022;349:7-16. [PMID: 35606078 DOI: 10.1016/j.atherosclerosis.2022.04.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]